BioCentury
ARTICLE | Company News

Chugai grants Lilly rights to preclinical diabetes candidate

October 5, 2018 8:07 PM UTC

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize preclinical Type II diabetes candidate OWL833. Chugai will receive $50 million up front and is eligible for undisclosed milestones and royalties.

OWL833 is an oral, glucagon-like peptide-1 receptor (GLP-1R; GLP1R) agonist...